Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
+1 212 318 2000
Europe, Middle East, & Africa
+44 20 7330 7500
+65 6212 1000
NEW BRUNSWICK, N.J.
Johnson & Johnson said Thursday it filed for marketing approval to the Food and Drug Administration of its drug canagliflozin, a once-per-day pill intended to treat Type 2 diabetes.
Canagliflozin is one of Johnson & Johnson's most promising drug candidates. The company's Janssen division has the right to market the drug in North and South America, Europe, the Middle East, Africa, Australia, New Zealand, and some Asian countries.
Shares of Johnson & Johnson rose 35 cents to $62.56 in morning trading.